Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?
1 Answers
Mednet Member
Gynecologic Oncology · University of California Irvine Medical Center
The phase II Keynote-158 indication is based on objective response of 14% in patients with PD-L1+ tumors. The US FDA approval is accelerated approval meaning that there needs to be a confirmatory trial - this is Keynote 826 which is ongoing.